ArticleDiscover oncology2026
Research progress and trends on PET/CT imaging of pancreatic cancer: a bibliometric analysis.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPositron Emission Tomography/Computed Tomography (PET/CT) imaging has emerged as an important tool with growing potential in the diagnosis, staging, and monitoring of pancreatic cancer, though its clinical implementation varies across different healthcare systems. This study aims to analyze the global research landscape and emerging trends in PET/CT for pancreatic cancer through a comprehensive bibliometric analysis.
methodsA bibliometric analysis was conducted using the Web of Science Core Collection to gather literature. The bibliometric tools VOSviewer, CiteSpace, and the R package “bibliometrix” were employed to visualize collaboration networks, keyword co-occurrences, and emerging research trends.
resultsThe analysis identified 381 publications on PET/CT in pancreatic cancer. The annual number of publications exhibited an overall increasing trend with a 13.56% annual growth rate. The USA led with 2,159 citations. Fudan University emerged as the most productive institution with 69 articles. The European Journal of Nuclear Medicine and Molecular Imaging ranked as the top publishing journal with 22 articles. Zuo Changjing was the most prolific author with 12 publications. Cluster analysis identified five research hotspots: treatment response and survival analysis, diagnostic accuracy and imaging characteristics, advanced imaging techniques and novel tracers, tumor biology and molecular imaging, and surgical planning and resectability assessment. Keyword analysis revealed evolving research hotspots, with recent emphasis on fibroblast activation protein (strength = 3.61, 2022–2024), survival (strength = 4.96, 2022–2024), and expression (strength = 5.91, 2019–2024).
conclusionThis bibliometric analysis identified five primary research hotspots, including diagnostic, prognostic, and therapeutic applications. Current and future research directions emphasize improving diagnostic accuracy, exploring novel molecular targets including fibroblast activation protein, and enhancing treatment response monitoring, suggesting PET/CT’s evolving potential in pancreatic cancer management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.